文献速递胃肠外科围术期管理与 ERAS

胃旁路术、袖状胃切除或强化生活方式干预后的阿片类药物使用

Opioid Use After Gastric Bypass, Sleeve Gastrectomy or Intensive Lifestyle Intervention.
PubMed 文献 · Ann Surg · 2023-01-27

这项全国性匹配队列研究比较了接受减重手术的肥胖患者与接受强化生活方式干预的肥胖成人的阿片类药物使用情况。手术组在术后3年(14.7% vs 8.9%)和8年(16.9% vs 9.0%)的阿片类药物处方患病率均高于生活方式组,且日均剂量差异随时间增大。结论认为减重手术与更高的阿片类药物使用比例和总剂量相关,尤其在随访期间接受额外手术的患者中更明显。

要点

  • 减重手术后3年阿片类药物处方率为14.7%,高于生活方式组的8.9%。
  • 术后8年手术组处方率为16.9%,生活方式组为9.0%。
  • 随访期间接受额外手术的患者阿片类药物使用增加更明显。

核心结论

  • 减重手术与更高的阿片类药物使用比例和更大总剂量相关,尤其在随访期间接受额外手术的患者中更明显。

研究设计与样本

  • 全国性匹配队列研究,纳入斯堪的纳维亚肥胖手术登记处和Itrim健康数据库的个体,匹配BMI、年龄、性别、教育、既往阿片使用、糖尿病、心血管疾病和精神状态,共30359对21356。
  • 数据来自瑞典处方药登记处,覆盖干预前2年至干预后最长8年。

主要发现

  • 治疗前2年,手术组和生活方式组接受至少1次阿片类药物处方的患病率相同。
  • 术后3年,手术组阿片类药物处方患病率为14.7%,生活方式组为8.9%(平均差异5.9%,95%CI 5.3-6.4)。
  • 术后8年,手术组处方患病率为16.9%,生活方式组为9.0%(平均差异7.9%,95%CI 6.8-9.0)。
  • 术后8年,手术组平均日剂量为3.55 mg,生活方式组为1.17 mg(基线剂量调整后平均差异2.30 mg,95%CI 1.61-2.98)。

临床怎么用

  • 减重术后应长期监测阿片类药物使用,尤其对需额外手术的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare opioid use in patients with obesity treated with bariatric surgery versus adults with obesity who underwent intensive lifestyle modification. SUMMARY OF BACKGROUND DATA: Previous studies of opioid use after bariatric surgery have been limited by small sample sizes, short follow-up, and lack of control groups. METHODS: Nationwide matched cohort study including individuals from the Scandinavian Obesity Surgery Registry and the Itrim health database with individuals undergoing structured intensive lifestyle modification, between August 1, 2007 and September 30, 2015. Participants were matched on Body Mass Index, age, sex, education, previous opioid use, diabetes, cardiovascular disease, and psychiatric status (n = 30,359:21,356). Dispensed opioids were retrieved from the Swedish Prescribed Drug Register from 2 years before to up to 8 years after intervention. RESULTS: During the 2-year period before treatment, prevalence of individuals receiving ≥1 opioid prescription was identical in the surgery and lifestyle group. At 3 years, the prevalence of opioid prescriptions was 14.7% versus 8.9% in the surgery and lifestyle groups (mean difference 5.9%, 95% confidence interval 5.3-6.4) and at 8 years 16.9% versus 9.0% (7.9%, 6.8-9.0). The difference in mean daily dose also increased over time and was 3.55 mg in the surgery group versus 1.17 mg in the lifestyle group at 8 years (mean difference [adjusted for baseline dose] 2.30 mg, 95% confidence interval 1.61-2.98). CONCLUSIONS: Bariatric surgery was associated with a higher proportion of opioid users and larger total opioid dose, compared to actively treated obese individuals. These trends were especially evident in patients who received additional surgery during follow-up.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Wallén S, Bruze G, Ottosson J, et al. Opioid Use After Gastric Bypass, Sleeve Gastrectomy or Intensive Lifestyle Intervention. Ann Surg. 2023. PMID: 36700782. doi:10.1097/SLA.0000000000005192

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。